Status:
COMPLETED
Hydration to Optimize Metabolism
Lead Sponsor:
Region Skane
Collaborating Sponsors:
Lund University
Danone Global Research & Innovation Center
Conditions:
Glucose, High Blood
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
This study evaluates hydration (1.5 L of water daily during 1 year) in the lowering of blood glucose concentration in adults with signs of dehydration (elevated levels of the vasopressin marker copept...
Detailed Description
High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease and premature death. The...
Eligibility Criteria
Inclusion
- Provision of informed consent, age 20-75 years with high plasma concentration of vasopressin (plasma concentration of copeptin of \> 6.1 pmol/L in women and \> 10.7 pmol/L in men) and 24 hour urine osmolality \> 600 milliosmol (mOsm) /kg water.
Exclusion
- 24 hour urine volume \> 1.5 L, pregnancy or breastfeeding, plasma sodium \< 135 mmol/L, use of diuretics, lithium or selective serotonin reuptake inhibitor (SSRI) drugs, chronic kidney disease (estimated glomerular filtration rate \< 30 mL/min), heart failure, inflammatory bowel disease, type 1 diabetes or type 2 diabetes treated with insulin, vulnerable subjects (subjects with legal guardian, with loss of personal liberty).
Key Trial Info
Start Date :
April 24 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2025
Estimated Enrollment :
797 Patients enrolled
Trial Details
Trial ID
NCT03422848
Start Date
April 24 2018
End Date
November 3 2025
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KFE, Skåne University Hospital in Malmö
Malmo, Sweden, SE-20502